From off-period dystonia to peak-dose chorea. The clinical spectrum of varying subthalamic nucleus activity.
暂无分享,去创建一个
A L Benabid | A Benazzouz | G. Deuschl | A. Benabid | P. Pollak | A. Benazzouz | P. Krack | G. Deuschl | P. Limousin | P Krack | P Pollak | P Limousin | G Deuschl
[1] R. Duvoisin,et al. Treatment of parkinsonism with levodopa. , 1969, Archives of neurology.
[2] Anthony E. Lang,et al. Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP patients requiring levodopa , 1996 .
[3] J. Penney,et al. The functional anatomy of basal ganglia disorders , 1989, Trends in Neurosciences.
[4] Y. Agid,et al. Does levodopa aggravate Parkinson's disease? , 1988, Neurology.
[5] M. Mark,et al. Ten years' experience with enteral levodopa infusions for motor fluctuations in Parkinson's disease , 1998, Movement disorders : official journal of the Movement Disorder Society.
[6] A Benazzouz,et al. Stimulation of subthalamic nucleus alleviates tremor in Parkinson's disease , 1997, The Lancet.
[7] D. Brooks,et al. Core assessment program for intracerebral transplantations (CAPIT) , 1992, Movement disorders : official journal of the Movement Disorder Society.
[8] W. Weiner,et al. Dystonic foot response of Parkinsonism. , 1980, Archives of neurology.
[9] Y. Agid,et al. Levodopa‐induced dyskinesias in Parkinson's disease phenomenology and pathophysiology , 1994, Movement disorders : official journal of the Movement Disorder Society.
[10] W. Gibb,et al. A comparison of clinical and pathological features of young‐ and old‐onset Parkinson's disease , 1988, Neurology.
[11] A. Benabid,et al. Effect on parkinsonian signs and symptoms of bilateral subthalamic nucleus stimulation , 1995, The Lancet.
[12] M. Hallett,et al. Pallidotomy for hemiballismus: Efficacy and characteristics of neuronal activity , 1997, Annals of neurology.
[13] W. Poewe,et al. Dystonia in parkinson's disease: Clinical and pharmacological features , 1988, Annals of neurology.
[14] W. Poewe,et al. Foot dystonia in Parkinson's disease: clinical phenomenology and neuropharmacology. , 1987, Advances in neurology.
[15] A. Barbeau. Long-term side-effects of levodopa. , 1971, Lancet.
[16] H. Bergman,et al. The primate subthalamic nucleus. II. Neuronal activity in the MPTP model of parkinsonism. , 1994, Journal of neurophysiology.
[17] H. Narabayashi,et al. Levodopa-induced dyskinesia and thalamotomy. , 1984, Journal of neurology, neurosurgery, and psychiatry.
[18] P. Bédard,et al. Cabergoline, a long-acting dopamine D2-like receptor agonist, produces a sustained antiparkinsonian effect with transient dyskinesias in parkinsonian drug-naive primates , 1996, Brain Research.
[19] J. Obeso,et al. The role of pulsatile versus continuous dopamine receptor stimulation for functional recovery in Parkinson's disease. , 1994, The European journal of neuroscience.
[20] J. Dostrovsky,et al. Effect of GPi pallidotomy on motor function in Parkinson's disease , 1995, The Lancet.
[21] M. Riklan,et al. Chemopallidectomy and chemothalamectomy for parkinsonism. , 1958, Geriatrics.
[22] A. Benabid,et al. Long-term suppression of tremor by chronic stimulation of the ventral intermediate thalamic nucleus , 1991, The Lancet.
[23] S. Fahn. Fluctuations of disability in Parkinson's disease: pathophysiology , 1981 .
[24] A. Benabid,et al. Chronic stimulation of subthalamic nucleus improves levodopa-induced dyskinesias in Parkinson's disease , 1997, The Lancet.
[25] A. Lang,et al. Utility of an objective dyskinesia rating scale for Parkinson's disease: Inter‐ and intrarater reliability assessment , 1994, Movement disorders : official journal of the Movement Disorder Society.
[26] F. Calon,et al. Continuous or pulsatile chronic D2 dopamine receptor agonist (U91356A) treatment of drug-naive 4-phenyl-1,2,3,6-tetrahydropyridine monkeys differentially regulates brain D1 and D2 receptor expression: in situ hybridization histochemical analysis , 1997, Neuroscience.
[27] J. P. Martin. HEMICHOREA RESULTING FROM A LOCAL LESION OF THE BRAIN. (THE SYNDROME OF THE BODY OF LUYS , 1927 .
[28] T. Engber,et al. Contribution of dopaminergic and glutamatergic mechanisms to the pathogenesis of motor response complications in Parkinson's disease. , 1996, Advances in neurology.
[29] M. Horstink,et al. Severity of Parkinson's disease is a risk factor for peak-dose dyskinesia. , 1990, Journal of neurology, neurosurgery, and psychiatry.
[30] B. Gomez-Mancilla,et al. DOPA-induced "peak dose" dyskinesia: clues implicating D2 receptor-mediated mechanisms using dopaminergic agonists in MPTP monkeys. , 1995, Journal of neural transmission. Supplementum.
[31] I. S. Cooper,et al. The effect of subcortical lesions on production and alleviation of hemiballic or hemichoreic movements. , 1966, Journal of the neurological sciences.
[32] F. Mundinger. [Subthalamotomy for the treatment of extrapyramidal movement disorders]. , 1965, Deutsche medizinische Wochenschrift.
[33] F. Mcdowell,et al. “Early” initiation of levodopa treatment does not promote the development of motor response fluctuations, dyskinesias, or dementia in Parkinson's disease , 1991, Neurology.
[34] Niall Quinn,et al. Young onset Parkinson's disease , 1987, Movement disorders : official journal of the Movement Disorder Society.
[35] George C. Cotzias,et al. Modification of Parkinsonism--chronic treatment with L-dopa. , 1969, The New England journal of medicine.
[36] Jean Siegfried,et al. Bilateral chronic electrostimulation of ventroposterolateral pallidum: a new therapeutic approach for alleviating all parkinsonian symptoms. , 1994 .
[37] A. Barbeau. L-dopa therapy in Parkinson's disease: a critical review of nine years' experience. , 1969, Canadian Medical Association journal.
[38] A. Benabid,et al. Electrical stimulation of the subthalamic nucleus in advanced Parkinson's disease. , 1998, The New England journal of medicine.
[39] L. Cote,et al. Painful dystonic spasms in Parkinson's disease. , 1984, Advances in neurology.
[40] Y. Agid,et al. Pathophysiology of L-dopa-induced abnormal involuntary movements. , 1985, Psychopharmacology. Supplementum.
[41] J. Obeso,et al. Levodopa‐induced dyskinesias in Parkinson's disease: Clinical and pharmacological classification , 1992, Movement disorders : official journal of the Movement Disorder Society.
[42] A. Barbeau. Six years of high-level levodopa therapy in severely akinetic parkinsonian patients. , 1976, Archives of neurology.
[43] S Blond,et al. Chronic thalamic stimulation improves tremor and levodopa induced dyskinesias in Parkinson's disease. , 1993, Journal of Neurology Neurosurgery & Psychiatry.
[44] L. Schiffer,et al. Aromatic amino acids and modification of parkinsonism. , 1967, The New England journal of medicine.
[45] B Bioulac,et al. Reversal of Rigidity and Improvement in Motor Performance by Subthalamic High‐frequency Stimulation in MPTP‐treated Monkeys , 1993, The European journal of neuroscience.
[46] A L Benabid,et al. Abnormal involuntary movements induced by subthalamic nucleus stimulation in parkinsonian patients , 1996, Movement disorders : official journal of the Movement Disorder Society.
[47] M. Sambrook,et al. Thalamotomy for the alleviation of levodopa-induced dyskinesia: Experimental studies in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated parkinsonian monkey , 1993, Neuroscience.
[48] P. Stewart. PARALYSIS AGITANS;: WITH AN ACCOUNT OF A NEW SYMPTOM , 1898 .
[49] I. S. Cooper. SURGICAL ALLEVIATION OF PARKINSONISM: EFFECTS OF OCCLUSION OF THE ANTERIOR CHOROIDAL ARTERY * , 1954, Journal of the American Geriatrics Society.
[50] A. Lees,et al. "OFF PERIOD" DYSTONIA AND "ON PERIOD" CHOREOATHETOSIS IN LEVODOPA-TREATED PATIENTS WITH PARKINSON'S DISEASE , 1977, The Lancet.
[51] N H Holford,et al. The response to levodopa in parkinson's disease: Imposing pharmacological law and order , 1996, Annals of neurology.
[52] M. Yahr,et al. Parkinson's disease and long-term levodopa therapy. , 1987, Advances in neurology.
[53] S. Fahn. Unified Parkinson's Disease Rating Scale , 1987 .
[54] A J Lees,et al. Continuous subcutaneous waking day apomorphine in the long term treatment of levodopa induced interdose dyskinesias in Parkinson’s disease , 1998, Journal of neurology, neurosurgery, and psychiatry.
[55] S. Gill,et al. Bilateral dorsolateral subthalamotomy for advanced Parkinson's disease , 1997, The Lancet.
[56] C. Gervason,et al. Levodopa‐induced diphasic dyskinesias improved by subcutaneous apomorphine , 1992, Movement disorders : official journal of the Movement Disorder Society.
[57] J. Dostrovsky,et al. Effects of apomorphine on globus pallidus neurons in parkinsonian patients , 1997, Annals of neurology.
[58] E. Melamed. Early-morning dystonia. A late side effect of long-term levodopa therapy in Parkinson's disease. , 1979, Archives of neurology.
[59] J. Bennett,et al. Suppression of dyskinesias in advanced Parkinson's disease , 1993, Neurology.
[60] L. Metman,et al. Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease , 1998, Neurology.
[61] A. Benabid,et al. Chronic electrical stimulation of the ventralis intermedius nucleus of the thalamus as a treatment of movement disorders. , 1996, Journal of neurosurgery.
[62] T. Chase,et al. Pathogenesis of dyskinesias in parkinson's disease , 1989, Annals of neurology.
[63] J. Schneider. Levodopa-induced dyskinesias in parkinsonian monkeys: Relationship to extent of nigrostriatal damage , 1989, Pharmacology Biochemistry and Behavior.
[64] A. Lang,et al. Severe evening dyskinesias in advanced Parkinson's disease: Clinical description, relation to plasma levodopa, and treatment , 2004, Movement disorders : official journal of the Movement Disorder Society.
[65] C. Marsden,et al. PAINFUL PARKINSON'S DISEASE , 1986, The Lancet.
[66] M. Muenter,et al. Patterns of dystonia ("I-D-I" and "D-I-D-") in response to l-dopa therapy for Parkinson's disease. , 1977, Mayo Clinic proceedings.
[67] A L Benabid,et al. Subthalamic nucleus or internal pallidal stimulation in young onset Parkinson's disease. , 1998, Brain : a journal of neurology.
[68] The pharmacology of foot dystonia in parkinsonism. , 1987, Clinical neuropharmacology.
[69] A. Benabid,et al. Opposite motor effects of pallidal stimulation in Parkinson's disease , 1998, Annals of neurology.
[70] A. Lees,et al. Beginning-of-dose motor deterioration following the acute administration of levodopa and apomorphine in Parkinson's disease. , 1992, Journal of neurology, neurosurgery, and psychiatry.
[71] C. Marsden,et al. Recent Developments in Parkinson's Disease , 1986 .
[72] M. Hariz,et al. Leksell's posteroventral pallidotomy in the treatment of Parkinson's disease. , 1992, Journal of neurosurgery.
[73] J. Dostrovsky,et al. Globus pallidus internus pallidotomy for generalized dystonia , 1997, Movement disorders : official journal of the Movement Disorder Society.
[74] L. Grégoire,et al. Risk Factors for Peak Dose Dyskinesia in 100 Levodopa-treated Parkinsonian Patients , 1996, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.
[75] P. Sonsalla,et al. Complex dystonia of Parkinson's disease: clinical features and relation to plasma levodopa profile. , 1990, Clinical neuropharmacology.
[76] S. Iversen,et al. Nigrostriatal damage is required for induction of dyskinesias by L-DOPA in squirrel monkeys. , 1990, Clinical neuropharmacology.
[77] C D Marsden,et al. Dopa‐responsive dystonia , 1991, Neurology.
[78] O. Devinsky,et al. Stereotactic ventral pallidotomy for Parkinson's disease , 1995, Neurology.
[79] R. Turner,et al. Treatment of advanced Parkinson's disease by posterior GPi pallidotomy: 1‐year results of a pilot study , 1996, Annals of neurology.
[80] M. Mark,et al. The rationale for continuous dopaminergic stimulation in patients with Parkinson's disease , 1992, Neurology.
[81] D. Calne,et al. Pallidotomy for tardive dyskinesia , 1997, The Lancet.
[82] H. Bergman,et al. Reversal of experimental parkinsonism by lesions of the subthalamic nucleus. , 1990, Science.
[83] Mones Rj,et al. Analysis of l-dopa induced dyskinesias in 51 patients with Parkinsonism , 1971 .
[84] J. Jankovic,et al. Pallidotomy for generalized dystonia , 1998, Movement disorders : official journal of the Movement Disorder Society.
[85] I. Heuser,et al. Modification of central dopaminergic mechanisms by continuous levodopa therapy for advanced Parkinson's disease , 1990, Annals of neurology.